{"id":"NCT01172145","sponsor":"Brown University","briefTitle":"Treatment of Apathy in Alzheimer's Disease With Modafinil","officialTitle":"Treatment of Apathy in Alzheimer's Disease With Modafinil","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":null,"completion":"2007-09","firstPosted":"2010-07-29","resultsPosted":"2011-03-04","lastUpdate":"2011-03-04"},"enrollment":22,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Apathy","Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Modafinil","otherNames":["Provigil"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cholinesterase inhibitor only","type":"PLACEBO_COMPARATOR"},{"label":"Cholinesterase Plus Modafinil","type":"EXPERIMENTAL"}],"summary":"This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).","primaryOutcome":{"measure":"Apathy","timeFrame":"at baseline","effectByArm":[{"arm":"Cholinesterase Inhibitor Only","deltaMin":88.91,"sd":11.95},{"arm":"Cholinesterase Plus Modafinil","deltaMin":95.64,"sd":10.79}],"pValues":[{"comp":"OG000 vs OG001","p":"0.181"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22687392"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Motor Tics"]}}